RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancerCharlotte K. Kindt(University of Southern Denmark), Carla L. Alves(University of Southern Denmark)Frontiers in OncologyJanuary 27, 202510.3389/fonc.2024.1497093Cited by 1SaveCiteExport RISWatch citationsRelated PapersCo-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer|Nature Communications|2021|82